U.S. Markets open in 1 hr 54 mins

Pipeline Progress at Prothena

Zacks Equity Research

Prothena Corporation (PRTA) has initiated a randomized, double-blind, placebo-controlled phase I trial on its monoclonal antibody candidate, PRX002.

PRX002 is being evaluated for the treatment of Parkinson's disease. The phase I trial will assess PRX002 for safety, tolerability, pharmacokinetics and immunogenicity.

The initiation of the trial has led to a $15 million milestone payment from Roche (RHHBY) to Prothena.

We remind investors that both the companies have entered into a worldwide collaboration agreement in Dec 2013. As per the agreement, both the companies will collaborate to develop and commercialize antibodies that target alpha-synuclein, including Prothena's PRX002.

Prothena has earned a total of $45 million through its worldwide PRX002 collaboration with Roche. The payment also includes the current milestone payment.

In addition, Prothena is also entitled for additional payments of up to $380 million upon achievement of development, regulatory and sales milestones along with an additional $175 million in milestone payments for sales outside the U.S. The total payments, both upfront and milestones, may amount up to $600 million on a global basis.

The agreement also provides Prothena with an option to co-promote PRX002 in the U.S. Both the companies have agreed to share all development and commercialization costs on a 70/30 basis (70% Roche and 30% Prothena) in the U.S. However, outside the U.S., Roche will be solely responsible for developing and commercializing PRX002 and pay Prothena up to double-digit royalties on net sales.

Moreover, Roche and Prothena will initiate a research collaboration focusing on optimizing early stage antibodies targeting alpha-synuclein. This research collaboration will include incorporation of Roche's proprietary Brain Shuttle(TM) technology to increase delivery of therapeutic antibodies to the brain.

Roche currently carries a Zacks Rank #4 (Sell) while Prothena carries a Zacks Rank #3 (Hold). Right now, other stocks like Forest Laboratories (FRX) and Shire (SHPG) look attractive in the healthcare sector, each with a Zacks Rank #2 (Buy).

Read the Full Research Report on RHHBY
Read the Full Research Report on FRX
Read the Full Research Report on SHPG
Read the Full Research Report on PRTA

Zacks Investment Research